DSM-5 criteria identified cannabis use disorder in 30% of chronic pain patients prescribed medical cannabis, but when accounting for therapeutic use context, the true rate dropped to about 2%.
Pain medicine specialists, addiction psychiatrists, medical cannabis prescribers
30% CUD by standard criteria vs. 2% when adjusted for therapeutic context
What the researchers found
Among 187 chronic pain patients prescribed medical cannabis, CUD prevalence was 29.9% using standard DSM-5 criteria, 13.9% when tolerance and withdrawal items were removed, and just 2.1% when positive items attributable to pain relief were excluded. Meanwhile, physicians identified abuse in only 1 patient, suggesting substantial underestimation from the clinical side.
Why it matters
The DSM-5 was not designed to diagnose substance use disorders in patients using a substance therapeutically. This study demonstrates how the diagnostic framework can produce dramatically different prevalence estimates depending on how criteria are interpreted.
The numbers in context
187 patients across 3 German pain centers; CUD prevalence: 29.9% (full DSM-5), 13.9% (without tolerance/withdrawal), 2.1% (adjusted for therapeutic context); 10.7% showed at least one abuse signal; 4.8% positive for nonprescribed drugs on urine test
How the study worked
Cross-sectional study using anonymous questionnaires and urine testing in 187 consecutive patients attending 3 German pain centers in 2021. DSM-5 criteria scored three ways: all criteria, without tolerance/withdrawal, and without pain-relief-motivated behaviors.
What this study cannot tell us
Cross-sectional design at German pain centers may not generalize internationally. Anonymous questionnaire format prevented linking individual responses to clinical records. The adjusted scoring method has not been validated independently.
How to read the evidence
Multi-center study with objective urine testing, though the adjusted scoring approach is novel and not yet independently validated.
When this study was published
Published 2023
The bigger picture
As medical cannabis prescriptions increase globally, the lack of appropriate diagnostic tools for identifying problematic use in therapeutic contexts becomes a growing clinical gap. Adapting or replacing DSM-5 criteria for this population is overdue.
Questions still open
- What validated screening tools could better distinguish therapeutic dependence from problematic use? How should clinicians monitor for cannabis use disorder in medical cannabis patients?
Common questions
Are standard addiction criteria accurate for medical cannabis patients?
Do doctors accurately detect cannabis misuse in pain patients?
Read the original research
Cannabis use disorder in patients with chronic pain: overestimation and underestimation in a cross-sectional observational study in 3 German pain management centres.
Pain, 164(6), 1303-1311
Citation
Bialas, Patric; Böttge-Wolpers, Claudia; Fitzcharles, Mary-Ann; Gottschling, Sven; Konietzke, Dieter; Juckenhöfel, Stephanie; Madlinger, Albrecht; Welsch, Patrick; Häuser, Winfried. (2023). Cannabis use disorder in patients with chronic pain: overestimation and underestimation in a cross-sectional observational study in 3 German pain management centres.. Pain, 164(6), 1303-1311. https://doi.org/10.1097/j.pain.0000000000002817
Explore the wider topic
- Physical vs Psychological Cannabis Dependence: What Science Actually Shows
- The Gap Between Cannabis Perception and Science: Why What We Believe Outpaces What We Know
- Cannabis Use Disorder: Am I Addicted? Self-Assessment Guide
- Cross-Addiction After Quitting Weed: When One Habit Replaces Another
- Is Weed Addictive? What the Research Actually Shows
- Is Cannabis Addictive? What the DSM-5 and Brain Science Say
- Quitting Weed and Alcohol Together: What to Know About Dual Cessation
- Is Rehab Necessary for Weed? An Honest Assessment
- Signs You May Have Cannabis Use Disorder: An Honest Self-Assessment
- Weed Vape Pen Addiction: Why Vaping Makes It Harder to Quit